Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab
The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus…